177 related articles for article (PubMed ID: 36717932)
21. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
[TBL] [Abstract][Full Text] [Related]
22. Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial.
Voigt S; Koemans EA; Rasing I; van Etten ES; Terwindt GM; Baas F; Kaushik K; van Es ACGM; van Buchem MA; van Osch MJP; van Walderveen MAA; Klijn CJM; Verbeek MM; van der Weerd L; Wermer MJH
Trials; 2023 Jun; 24(1):378. PubMed ID: 37277877
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
[TBL] [Abstract][Full Text] [Related]
24. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2.
Tayebjee MH; Lip GY; Blann AD; Macfadyen RJ
Thromb Res; 2005; 115(3):205-10. PubMed ID: 15617743
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid.
Kolb SA; Lahrtz F; Paul R; Leppert D; Nadal D; Pfister HW; Fontana A
J Neuroimmunol; 1998 Apr; 84(2):143-50. PubMed ID: 9628456
[TBL] [Abstract][Full Text] [Related]
26. Optical coherence tomography detects retinal changes in hereditary cerebral amyloid angiopathy.
van Etten ES; de Boer I; Steenmeijer SR; Al-Nofal M; Wermer MJH; Notting IC; Terwindt GM
Eur J Neurol; 2020 Dec; 27(12):2635-2640. PubMed ID: 32894579
[TBL] [Abstract][Full Text] [Related]
27. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
[TBL] [Abstract][Full Text] [Related]
28. Subarachnoid CSF hyperintensities at 7 tesla FLAIR MRI: A novel marker in cerebral amyloid angiopathy.
Koemans EA; van Walderveen MAA; Voigt S; Rasing I; van Harten TW; J A van Os H; van der Weerd N; Terwindt GM; van Osch MJP; van Veluw SJ; Freeze WM; Wermer MJH
Neuroimage Clin; 2023; 38():103386. PubMed ID: 36989852
[TBL] [Abstract][Full Text] [Related]
29. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
[TBL] [Abstract][Full Text] [Related]
30. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
31. Diabetes may affect the expression of matrix metalloproteinases and their inhibitors more than smoking in chronic periodontitis.
Bastos MF; Tucci MA; de Siqueira A; de Faveri M; Figueiredo LC; Vallim PC; Duarte PM
J Periodontal Res; 2017 Apr; 52(2):292-299. PubMed ID: 27363729
[TBL] [Abstract][Full Text] [Related]
32. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization.
Ma DH; Chen JK; Kim WS; Hao YX; Wu HC; Tsai RJ; Hwang DG; Zhang F
Ophthalmic Res; 2001; 33(6):353-62. PubMed ID: 11721189
[TBL] [Abstract][Full Text] [Related]
33. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
[TBL] [Abstract][Full Text] [Related]
34. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in joint fluid of the patients with loose artificial hip joints.
Takei I; Takagi M; Santavirta S; Ida H; Hamasaki M; Ishii M; Fukushima S; Ogino T; Konttinen YT
J Biomed Mater Res; 1999 Jun; 45(3):175-83. PubMed ID: 10397973
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of inductive effects of different concentrations of cyclosporine A on MMP-1, MMP-2, MMP-3, TIMP-1, and TIMP-2 in fetal and adult human gingival fibroblasts.
Nazemisalman B; Sajedinejad N; Darvish S; Vahabi S; Gudarzi H
J Basic Clin Physiol Pharmacol; 2019 Mar; 30(3):. PubMed ID: 30913036
[TBL] [Abstract][Full Text] [Related]
37. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
38. Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations.
Chatterjee P; Fagan AM; Xiong C; McKay M; Bhatnagar A; Wu Y; Singh AK; Taddei K; Martins I; Gardener SL; Molloy MP; Multhaup G; Masters CL; Schofield PR; Benzinger TLS; Morris JC; Bateman RJ; Greenberg SM; Wermer MJH; van Buchem MA; Sohrabi HR; Martins RN;
J Alzheimers Dis; 2021; 79(2):895-903. PubMed ID: 33361604
[TBL] [Abstract][Full Text] [Related]
39. Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis-affected gingival tissue.
Kubota T; Itagaki M; Hoshino C; Nagata M; Morozumi T; Kobayashi T; Takagi R; Yoshie H
J Periodontol; 2008 Jan; 79(1):166-73. PubMed ID: 18166107
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinases are associated with severity of disease among COVID-19 patients: A possible pharmacological target.
Cavalcante GL; Bonifacio LP; Sanches-Lopes JM; Puga FG; de Carvalho FS; Bellissimo-Rodrigues F; Tanus-Santos JE
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):727-736. PubMed ID: 38468413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
